Cargando…
A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol)
BACKGROUND: Paclitaxel is a standard of care for patients with primary cutaneous angiosarcoma of the scalp and face. However, no standard second-line treatment for paclitaxel-resistant patients has ever been established. Since primary cutaneous angiosarcoma expresses a high level of vascular endothe...
Autores principales: | Oashi, Kohei, Shibata, Taro, Namikawa, Kenjiro, Takahashi, Akira, Yokota, Kenji, Nakano, Eiji, Teramoto, Yukiko, Tsutsumida, Arata, Maeda, Taku, Yamazaki, Naoya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359578/ https://www.ncbi.nlm.nih.gov/pubmed/32660439 http://dx.doi.org/10.1186/s12885-020-07136-1 |
Ejemplares similares
-
Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan Clinical Oncology Group study (JCOG1602, J-NAIL study protocol)
por: Tanaka, Kiyo, et al.
Publicado: (2019) -
Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)
por: Namikawa, Kenjiro, et al.
Publicado: (2017) -
Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)
por: Nakamura, Nobuhiko, et al.
Publicado: (2021) -
Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910
por: Shida, Dai, et al.
Publicado: (2023) -
HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1)
por: Ri, Masaki, et al.
Publicado: (2021)